HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor with pIC 50 s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity
In Vitro
HDAC-IN-4 inhibits HDAC1, HDAC2, HDAC3, HDAC8 and HDAC10 with pIC 50 s of 5.5, 4.6, 5.4, 5.4, 6.7 in FRET assay, respectively. HDAC-IN-4 is more potent against HDAC6 than Tubastatin A, suggests that HDAC-IN-4 may be a better HDAC6 probe than Tubastatin A. MCE has not independently confirmed the accuracy of these methods. They are for reference only.